While the roster of products used to address these skin concerns are limited in order to protect your babys healthy development, innovation and discovery in the skincare world have brought safe and effective products into the fold
Standard dosing is evidence-based, while microdosing, using lower-than-prescribed doses, has gained attention despite limited evidence, with potential benefits offset by concerns about reduced efficacy, safety risks, and lack of clinical validation
These medications carry precautions, including a history of medullary thyroid carcinoma, MEN2, pancreatitis, or gallbladder disease, and this is not a complete list
Every clinic should make it this easy
Canadian Employer Plans Covering GLP-1s for Weight Loss Have Nearly Doubled Data from the International Foundation of Employee Benefit Plans (IFEBP) 2025 Pulse Survey shows a significant shift in Canadian employer attitudes toward GLP-1 coverage: 31% of employer plans now cover GLP-1s for weight loss (up from 17% in 2024) 56% cover for diabetes only (down from 66% in 2024) 20% of diabetes-only plans are considering adding obesity coverage Provincial public drug plans still cover semaglutide only for type 2 diabetes not for weight loss
These quantification results were presented as the Mean SD